Bicycle Therapeutics PLC (NASDAQ:BCYC)
| 15.70 Delayed Data As of 3:59pm ET |  +1.17 / +8.05%Today’s Change | 12.54 Today|||52-Week Range 33.49 | -46.96% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $635.1M |
Company Description
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Contact Information
Bicycle Therapeutics Plc Granta Park Great Abington Cambridge Cambridgeshire CB21 6GS |
Employees
Shareholders
| Other institutional | 75.89% |
| Mutual fund holders | 18.22% |
| Individual stakeholders | -- |
Top Executives
| Kevin Lee | Chief Executive Officer & Executive Director |
| Alistair Milnes | Chief Operating Officer |
| Alethia Rene Young | Chief Financial Officer |
| Michael Skynner | Chief Technology Officer |
| Nicholas Keen | Chief Scientific Officer |
